BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
Research Pipeline · 25 Jul 2026
MOTS-c: The Mitochondria-Encoded Peptide With a Decade of Preclinical Evidence and a Critical FDA Compounding Vote Eleven Days Away
MOTS-c, a 16-amino acid peptide encoded within mitochondrial DNA, is set for formal FDA advisory review on 23 July 2026 as part of the PCAC's evaluation of seven peptides for the 503A Bulk Drug Substances List. FDA briefing documents propose that it should not be listed, citing insufficient human data and characterisation gaps — yet a Phase 2a trial in prediabetes is now registered, adding new urgency to procurement decisions for UK research labs.
Read briefing →
Research Pipeline
KPV: The Alpha-MSH Tripeptide With Two Decades of Preclinical Evidence and an FDA Compounding Vote Nine Days Away
KPV (Lys-Pro-Val) is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone with a substantive body of preclinical evidence in inflammatory bowel disease, wound healing, and dermatology. On 23 July 2026, it faces its first formal FDA scientific review at the Pharmacy Compounding Advisory Committee — and the agency's own briefing documents lean against listing it on the 503A Bulk Drug Substances List.
25 Jul 2026
Research Pipeline
Thymosin Alpha-1: The Thymic Peptide With Four Decades of Clinical Evidence and a Divided Global Regulatory Map
Thymosin alpha-1 (Tα1) occupies a singular position in the peptide landscape: it is approved as a prescription medicine in more than 35 countries under the brand name Zadaxin, yet it holds no FDA approval in the United States and no MHRA marketing authorisation in the UK. This briefing reviews the compound's mechanism, the depth of its clinical evidence base, its evolving US compounding status, and what the regulatory asymmetry means for UK research-procurement professionals.
25 Jul 2026
Research Pipeline
Emideltide (DSIP): The Nine-Amino-Acid Sleep Peptide With Five Decades of Mixed Evidence Now Facing Its First FDA Compounding Review
Delta sleep-inducing peptide — designated Emideltide in US regulatory materials — is the least-discussed substance on the FDA Pharmacy Compounding Advisory Committee's July 24 agenda. Its clinical evidence base is older and narrower than many peptides in the grey market, yet it covers two areas of genuine unmet need: treatment-resistant insomnia and opioid withdrawal. FDA staff scientists have already recommended against listing it, setting up a pointed test of how the reconstituted advisory…
25 Jul 2026
Regulatory & Policy
Semax: The Russian Neuropeptide Facing Its First US Compounding Vote in Six Days — and a Hostile FDA Briefing Document
Semax, a synthetic heptapeptide approved in Russia since 2011 for neurological indications, goes before the FDA's Pharmacy Compounding Advisory Committee on 24 July 2026. FDA career scientists have already recommended against adding it — and six other peptides — to the 503A Bulks List, citing inadequate characterisation and absent human safety data. The committee's non-binding vote will nonetheless shape the regulatory trajectory for compounding access in the US and, indirectly, procurement…
25 Jul 2026
Regulatory & Policy
FDA's Two-Track Compounding Posture: Closing the Door on Approved GLP-1s While Opening a New Review for Novel Peptides
The FDA is simultaneously moving to permanently bar large-scale compounding of semaglutide, tirzepatide and liraglutide from the 503B Bulks List, while convening a Pharmacy Compounding Advisory Committee meeting on 23–24 July 2026 to consider opening regulated compounding pathways for seven novel, currently unapproved peptides. Research-procurement professionals need to understand how these two tracks interact — and what each means for sourcing decisions.
25 Jul 2026
Research Pipeline
TB-500: The Thymosin Beta-4 Fragment Facing a Hostile FDA Briefing Document Four Days Before Its First Compounding Vote
TB-500, a synthetic seven-amino-acid fragment of thymosin beta-4, is scheduled for review by the FDA's Pharmacy Compounding Advisory Committee on 23 July 2026. The agency's pre-published briefing document proposes that neither the free base nor the acetate form be added to the 503A Bulk Drug Substances List, citing failures of chemical characterisation and an absence of adequate human clinical evidence for wound healing.
25 Jul 2026
Industry & Community
Samsung Biologics Bids $1.8 Billion for Swiss Peptide CDMO PolyPeptide Group in Korea's Largest-Ever Pharma Deal
Samsung Biologics launched an all-cash public tender offer of CHF 1.46 billion ($1.8 billion) for Switzerland's PolyPeptide Group on 20 July 2026 — the largest biopharmaceutical M&A transaction in South Korean history. The deal brings a 70-year-old peptide CDMO, six GMP-certified manufacturing sites, and direct exposure to GLP-1 API demand under Samsung Biologics' roof, and signals how urgently global CDMO operators are moving to secure peptide manufacturing capacity ahead of a projected $29…
25 Jul 2026
Industry & Community
The Oral GLP-1 Race in 2026: What the Shift from Peptide Injections to Small-Molecule Pills Means for the Research Supply Chain
The MHRA approved the first oral GLP-1 tablet for weight loss in June 2026, and the FDA followed with orforglipron (Foundayo) — the first non-peptide small-molecule GLP-1 — in April. Head-to-head trial data now favour the small-molecule entrant on both glycaemic control and weight loss, raising structural questions for peptide API manufacturers and research-grade suppliers about where future demand will concentrate.
25 Jul 2026
Research Pipeline
Epitalon: The Telomere Tetrapeptide Heading Into Its First FDA Compounding Vote Tomorrow
Epitalon — a synthetic four-amino-acid peptide derived from pineal gland extract — faces its first formal FDA compounding review on 24 July 2026, the second day of the PCAC meeting at White Oak. With fresh independent evidence from a 2025 Biogerontology study, a negative FDA staff recommendation, and reported conflicts of interest on the panel itself, the regulatory moment is more contested than the peptide's three decades of largely preclinical research would suggest.
25 Jul 2026
Research Pipeline
Tesamorelin: The Only FDA-Approved GHRH Peptide — and What Its Regulatory Journey Tells the Research Community
Tesamorelin (Egrifta) stands apart from the peptides currently before the FDA's Pharmacy Compounding Advisory Committee: it already holds three successive FDA approvals, backed by Phase III randomised controlled trials. Understanding how it got there — and what that means for compounding access, off-label research, and the GHRH class more broadly — is increasingly relevant for procurement professionals as the July 2026 PCAC meeting unfolds.
25 Jul 2026
Regulatory & Policy
PCAC Votes to Recommend All Four Day-One Peptides Over FDA Scientists' Objections — What Comes Next for the Research Supply Chain
The FDA's Pharmacy Compounding Advisory Committee voted on 23 July to recommend BPC-157, KPV, TB-500 and MOTS-c for inclusion on the 503A Bulk Drug Substances List, defying its own career scientists on every substance. Day two votes on Semax, Epitalon and Emideltide followed on 24 July. A formal rulemaking process of eight to eighteen months now stands between the recommendations and any change in legal compounding status — and five further peptides await a second PCAC meeting before the end…
25 Jul 2026